Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$39.16 USD

39.16
2,512,037

+0.26 (0.67%)

Updated Jul 12, 2024 03:59 PM ET

Pre-Market: $39.05 -0.11 (-0.28%) 9:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DNL

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

by Zacks Equity Research

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment

by Zacks Equity Research

Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.

Glaxo (GSK) Down 3.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer's (PFE) RSV Vaccine Abrysvo Gets Approval in EU

by Zacks Equity Research

Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.

Here's Why GSK (GSK) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak

by Zacks Equity Research

Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.

Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women

by Zacks Equity Research

The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.

Ekta Bagri headshot

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

by Ekta Bagri

We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.

The Zacks Analyst Blog Highlights Microsoft, Mastercard, ServiceNow, Lowe's and GSK

by Zacks Equity Research

Microsoft, Mastercard, ServiceNow, Lowe's and GSK are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Microsoft, Mastercard & ServiceNow

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA) and ServiceNow, Inc. (NOW).

Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology

by Zacks Equity Research

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.

Sheraz Mian headshot

Top Stock Reports for Walt Disney, Boeing & General Electric

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), The Boeing Company (BA) and General Electric Company (GE).

Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.

Stock Market News for Jul 27, 2023

by Zacks Equity Research

U.S. stocks ended mixed on Wednesday, with the S&P 500 and the Nasdaq ending slightly lower, as major indexes made a failed attempt to bounce back after the Fed hiked interest rates yet again.

GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.

Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More

by Zacks Equity Research

Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.

GSK (GSK) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 14.12% and 5.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bristol-Myers (BMY) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.

GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

Vir Biotechnology (VIR) Down on Influenza Study Failure

by Zacks Equity Research

Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.

Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.